Cargando…

Nanopore metagenomic sequencing of influenza virus directly from respiratory samples: diagnosis, drug resistance and nosocomial transmission, United Kingdom, 2018/19 influenza season

BACKGROUND: Influenza virus presents a considerable challenge to public health by causing seasonal epidemics and occasional pandemics. Nanopore metagenomic sequencing has the potential to be deployed for near-patient testing, providing rapid infection diagnosis, rationalising antimicrobial therapy,...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Yifei, Lewandowski, Kuiama, Downs, Louise O, Kavanagh, James, Hender, Thomas, Lumley, Sheila, Jeffery, Katie, Foster, Dona, Sanderson, Nicholas D, Vaughan, Ali, Morgan, Marcus, Vipond, Richard, Carroll, Miles, Peto, Timothy, Crook, Derrick, Walker, A Sarah, Matthews, Philippa C, Pullan, Steven T
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Centre for Disease Prevention and Control (ECDC) 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8268652/
https://www.ncbi.nlm.nih.gov/pubmed/34240696
http://dx.doi.org/10.2807/1560-7917.ES.2021.26.27.2000004
_version_ 1783720404812038144
author Xu, Yifei
Lewandowski, Kuiama
Downs, Louise O
Kavanagh, James
Hender, Thomas
Lumley, Sheila
Jeffery, Katie
Foster, Dona
Sanderson, Nicholas D
Vaughan, Ali
Morgan, Marcus
Vipond, Richard
Carroll, Miles
Peto, Timothy
Crook, Derrick
Walker, A Sarah
Matthews, Philippa C
Pullan, Steven T
author_facet Xu, Yifei
Lewandowski, Kuiama
Downs, Louise O
Kavanagh, James
Hender, Thomas
Lumley, Sheila
Jeffery, Katie
Foster, Dona
Sanderson, Nicholas D
Vaughan, Ali
Morgan, Marcus
Vipond, Richard
Carroll, Miles
Peto, Timothy
Crook, Derrick
Walker, A Sarah
Matthews, Philippa C
Pullan, Steven T
author_sort Xu, Yifei
collection PubMed
description BACKGROUND: Influenza virus presents a considerable challenge to public health by causing seasonal epidemics and occasional pandemics. Nanopore metagenomic sequencing has the potential to be deployed for near-patient testing, providing rapid infection diagnosis, rationalising antimicrobial therapy, and supporting infection-control interventions. AIM: To evaluate the applicability of this sequencing approach as a routine laboratory test for influenza in clinical settings. METHODS: We conducted Oxford Nanopore Technologies (Oxford, United Kingdom (UK)) metagenomic sequencing for 180 respiratory samples from a UK hospital during the 2018/19 influenza season, and compared results to routine molecular diagnostic standards (Xpert Xpress Flu/RSV assay; BioFire FilmArray Respiratory Panel 2 assay). We investigated drug resistance, genetic diversity, and nosocomial transmission using influenza sequence data. RESULTS: Compared to standard testing, Nanopore metagenomic sequencing was 83% (75/90) sensitive and 93% (84/90) specific for detecting influenza A viruses. Of 59 samples with haemagglutinin subtype determined, 40 were H1 and 19 H3. We identified an influenza A(H3N2) genome encoding the oseltamivir resistance S331R mutation in neuraminidase, potentially associated with an emerging distinct intra-subtype reassortant. Whole genome phylogeny refuted suspicions of a transmission cluster in a ward, but identified two other clusters that likely reflected nosocomial transmission, associated with a predominant community-circulating strain. We also detected other potentially pathogenic viruses and bacteria from the metagenome. CONCLUSION: Nanopore metagenomic sequencing can detect the emergence of novel variants and drug resistance, providing timely insights into antimicrobial stewardship and vaccine design. Full genome generation can help investigate and manage nosocomial outbreaks.
format Online
Article
Text
id pubmed-8268652
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher European Centre for Disease Prevention and Control (ECDC)
record_format MEDLINE/PubMed
spelling pubmed-82686522021-07-16 Nanopore metagenomic sequencing of influenza virus directly from respiratory samples: diagnosis, drug resistance and nosocomial transmission, United Kingdom, 2018/19 influenza season Xu, Yifei Lewandowski, Kuiama Downs, Louise O Kavanagh, James Hender, Thomas Lumley, Sheila Jeffery, Katie Foster, Dona Sanderson, Nicholas D Vaughan, Ali Morgan, Marcus Vipond, Richard Carroll, Miles Peto, Timothy Crook, Derrick Walker, A Sarah Matthews, Philippa C Pullan, Steven T Euro Surveill Research BACKGROUND: Influenza virus presents a considerable challenge to public health by causing seasonal epidemics and occasional pandemics. Nanopore metagenomic sequencing has the potential to be deployed for near-patient testing, providing rapid infection diagnosis, rationalising antimicrobial therapy, and supporting infection-control interventions. AIM: To evaluate the applicability of this sequencing approach as a routine laboratory test for influenza in clinical settings. METHODS: We conducted Oxford Nanopore Technologies (Oxford, United Kingdom (UK)) metagenomic sequencing for 180 respiratory samples from a UK hospital during the 2018/19 influenza season, and compared results to routine molecular diagnostic standards (Xpert Xpress Flu/RSV assay; BioFire FilmArray Respiratory Panel 2 assay). We investigated drug resistance, genetic diversity, and nosocomial transmission using influenza sequence data. RESULTS: Compared to standard testing, Nanopore metagenomic sequencing was 83% (75/90) sensitive and 93% (84/90) specific for detecting influenza A viruses. Of 59 samples with haemagglutinin subtype determined, 40 were H1 and 19 H3. We identified an influenza A(H3N2) genome encoding the oseltamivir resistance S331R mutation in neuraminidase, potentially associated with an emerging distinct intra-subtype reassortant. Whole genome phylogeny refuted suspicions of a transmission cluster in a ward, but identified two other clusters that likely reflected nosocomial transmission, associated with a predominant community-circulating strain. We also detected other potentially pathogenic viruses and bacteria from the metagenome. CONCLUSION: Nanopore metagenomic sequencing can detect the emergence of novel variants and drug resistance, providing timely insights into antimicrobial stewardship and vaccine design. Full genome generation can help investigate and manage nosocomial outbreaks. European Centre for Disease Prevention and Control (ECDC) 2021-07-08 /pmc/articles/PMC8268652/ /pubmed/34240696 http://dx.doi.org/10.2807/1560-7917.ES.2021.26.27.2000004 Text en This article is copyright of the authors or their affiliated institutions, 2021. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution (CC BY 4.0) Licence. You may share and adapt the material, but must give appropriate credit to the source, provide a link to the licence, and indicate if changes were made.
spellingShingle Research
Xu, Yifei
Lewandowski, Kuiama
Downs, Louise O
Kavanagh, James
Hender, Thomas
Lumley, Sheila
Jeffery, Katie
Foster, Dona
Sanderson, Nicholas D
Vaughan, Ali
Morgan, Marcus
Vipond, Richard
Carroll, Miles
Peto, Timothy
Crook, Derrick
Walker, A Sarah
Matthews, Philippa C
Pullan, Steven T
Nanopore metagenomic sequencing of influenza virus directly from respiratory samples: diagnosis, drug resistance and nosocomial transmission, United Kingdom, 2018/19 influenza season
title Nanopore metagenomic sequencing of influenza virus directly from respiratory samples: diagnosis, drug resistance and nosocomial transmission, United Kingdom, 2018/19 influenza season
title_full Nanopore metagenomic sequencing of influenza virus directly from respiratory samples: diagnosis, drug resistance and nosocomial transmission, United Kingdom, 2018/19 influenza season
title_fullStr Nanopore metagenomic sequencing of influenza virus directly from respiratory samples: diagnosis, drug resistance and nosocomial transmission, United Kingdom, 2018/19 influenza season
title_full_unstemmed Nanopore metagenomic sequencing of influenza virus directly from respiratory samples: diagnosis, drug resistance and nosocomial transmission, United Kingdom, 2018/19 influenza season
title_short Nanopore metagenomic sequencing of influenza virus directly from respiratory samples: diagnosis, drug resistance and nosocomial transmission, United Kingdom, 2018/19 influenza season
title_sort nanopore metagenomic sequencing of influenza virus directly from respiratory samples: diagnosis, drug resistance and nosocomial transmission, united kingdom, 2018/19 influenza season
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8268652/
https://www.ncbi.nlm.nih.gov/pubmed/34240696
http://dx.doi.org/10.2807/1560-7917.ES.2021.26.27.2000004
work_keys_str_mv AT xuyifei nanoporemetagenomicsequencingofinfluenzavirusdirectlyfromrespiratorysamplesdiagnosisdrugresistanceandnosocomialtransmissionunitedkingdom201819influenzaseason
AT lewandowskikuiama nanoporemetagenomicsequencingofinfluenzavirusdirectlyfromrespiratorysamplesdiagnosisdrugresistanceandnosocomialtransmissionunitedkingdom201819influenzaseason
AT downslouiseo nanoporemetagenomicsequencingofinfluenzavirusdirectlyfromrespiratorysamplesdiagnosisdrugresistanceandnosocomialtransmissionunitedkingdom201819influenzaseason
AT kavanaghjames nanoporemetagenomicsequencingofinfluenzavirusdirectlyfromrespiratorysamplesdiagnosisdrugresistanceandnosocomialtransmissionunitedkingdom201819influenzaseason
AT henderthomas nanoporemetagenomicsequencingofinfluenzavirusdirectlyfromrespiratorysamplesdiagnosisdrugresistanceandnosocomialtransmissionunitedkingdom201819influenzaseason
AT lumleysheila nanoporemetagenomicsequencingofinfluenzavirusdirectlyfromrespiratorysamplesdiagnosisdrugresistanceandnosocomialtransmissionunitedkingdom201819influenzaseason
AT jefferykatie nanoporemetagenomicsequencingofinfluenzavirusdirectlyfromrespiratorysamplesdiagnosisdrugresistanceandnosocomialtransmissionunitedkingdom201819influenzaseason
AT fosterdona nanoporemetagenomicsequencingofinfluenzavirusdirectlyfromrespiratorysamplesdiagnosisdrugresistanceandnosocomialtransmissionunitedkingdom201819influenzaseason
AT sandersonnicholasd nanoporemetagenomicsequencingofinfluenzavirusdirectlyfromrespiratorysamplesdiagnosisdrugresistanceandnosocomialtransmissionunitedkingdom201819influenzaseason
AT vaughanali nanoporemetagenomicsequencingofinfluenzavirusdirectlyfromrespiratorysamplesdiagnosisdrugresistanceandnosocomialtransmissionunitedkingdom201819influenzaseason
AT morganmarcus nanoporemetagenomicsequencingofinfluenzavirusdirectlyfromrespiratorysamplesdiagnosisdrugresistanceandnosocomialtransmissionunitedkingdom201819influenzaseason
AT vipondrichard nanoporemetagenomicsequencingofinfluenzavirusdirectlyfromrespiratorysamplesdiagnosisdrugresistanceandnosocomialtransmissionunitedkingdom201819influenzaseason
AT carrollmiles nanoporemetagenomicsequencingofinfluenzavirusdirectlyfromrespiratorysamplesdiagnosisdrugresistanceandnosocomialtransmissionunitedkingdom201819influenzaseason
AT petotimothy nanoporemetagenomicsequencingofinfluenzavirusdirectlyfromrespiratorysamplesdiagnosisdrugresistanceandnosocomialtransmissionunitedkingdom201819influenzaseason
AT crookderrick nanoporemetagenomicsequencingofinfluenzavirusdirectlyfromrespiratorysamplesdiagnosisdrugresistanceandnosocomialtransmissionunitedkingdom201819influenzaseason
AT walkerasarah nanoporemetagenomicsequencingofinfluenzavirusdirectlyfromrespiratorysamplesdiagnosisdrugresistanceandnosocomialtransmissionunitedkingdom201819influenzaseason
AT matthewsphilippac nanoporemetagenomicsequencingofinfluenzavirusdirectlyfromrespiratorysamplesdiagnosisdrugresistanceandnosocomialtransmissionunitedkingdom201819influenzaseason
AT pullanstevent nanoporemetagenomicsequencingofinfluenzavirusdirectlyfromrespiratorysamplesdiagnosisdrugresistanceandnosocomialtransmissionunitedkingdom201819influenzaseason